Oncotelic Therapeutics Probability of Future OTC Stock Price Finishing Over 0.022
| OTLCDelisted Stock | USD 0.02 0 6.38% |
Oncotelic |
Oncotelic Therapeutics Target Price Odds to finish over 0.022
The tendency of Oncotelic OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.02 | 90 days | 0.02 | about 88.68 |
Based on a normal probability distribution, the odds of Oncotelic Therapeutics to move above the current price in 90 days from now is about 88.68 (This Oncotelic Therapeutics probability density function shows the probability of Oncotelic OTC Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Oncotelic Therapeutics has a beta of -0.0175. This indicates as returns on the benchmark increase, returns on holding Oncotelic Therapeutics are expected to decrease at a much lower rate. During a bear market, however, Oncotelic Therapeutics is likely to outperform the market. Additionally Oncotelic Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Oncotelic Therapeutics Price Density |
| Price |
Predictive Modules for Oncotelic Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Oncotelic Therapeutics. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Oncotelic Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Oncotelic Therapeutics is not an exception. The market had few large corrections towards the Oncotelic Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Oncotelic Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Oncotelic Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.26 | |
β | Beta against Dow Jones | -0.02 | |
σ | Overall volatility | 0.01 | |
Ir | Information ratio | -0.03 |
Oncotelic Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Oncotelic Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Oncotelic Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Oncotelic Therapeutics is not yet fully synchronised with the market data | |
| Oncotelic Therapeutics has some characteristics of a very speculative penny stock | |
| Oncotelic Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Oncotelic Therapeutics currently holds 9.8 M in liabilities with Debt to Equity (D/E) ratio of 0.4, which is about average as compared to similar companies. Oncotelic Therapeutics has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Oncotelic Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Oncotelic Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Oncotelic Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Oncotelic to invest in growth at high rates of return. When we think about Oncotelic Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (9.39 M) with profit before overhead, payroll, taxes, and interest of 1.74 M. | |
| Oncotelic Therapeutics currently holds about 399.77 K in cash with (4.43 M) of positive cash flow from operations. | |
| Roughly 56.0% of Oncotelic Therapeutics outstanding shares are owned by corporate insiders |
Oncotelic Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Oncotelic OTC Stock often depends not only on the future outlook of the current and potential Oncotelic Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Oncotelic Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 375.3 M |
Oncotelic Therapeutics Technical Analysis
Oncotelic Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Oncotelic OTC Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Oncotelic Therapeutics. In general, you should focus on analyzing Oncotelic OTC Stock price patterns and their correlations with different microeconomic environments and drivers.
Oncotelic Therapeutics Predictive Forecast Models
Oncotelic Therapeutics' time-series forecasting models is one of many Oncotelic Therapeutics' otc stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Oncotelic Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the otc stock market movement and maximize returns from investment trading.
Things to note about Oncotelic Therapeutics
Checking the ongoing alerts about Oncotelic Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Oncotelic Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Oncotelic Therapeutics is not yet fully synchronised with the market data | |
| Oncotelic Therapeutics has some characteristics of a very speculative penny stock | |
| Oncotelic Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Oncotelic Therapeutics currently holds 9.8 M in liabilities with Debt to Equity (D/E) ratio of 0.4, which is about average as compared to similar companies. Oncotelic Therapeutics has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Oncotelic Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Oncotelic Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Oncotelic Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Oncotelic to invest in growth at high rates of return. When we think about Oncotelic Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (9.39 M) with profit before overhead, payroll, taxes, and interest of 1.74 M. | |
| Oncotelic Therapeutics currently holds about 399.77 K in cash with (4.43 M) of positive cash flow from operations. | |
| Roughly 56.0% of Oncotelic Therapeutics outstanding shares are owned by corporate insiders |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Oncotelic OTC Stock
If you are still planning to invest in Oncotelic Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncotelic Therapeutics' history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |